

RESPIRI

A Breath of Fresh Ideas




Shareholder Update

28 March 2019

MANUFACTURING

- wheezo™ plastics tuning process complete
- 20 pre-production units for beta testing completed
- SRX electronic assemblies completed and tested
- Assembly of 100 pre-production units with final plastics scheduled for 8 April
- Safety & Compliance testing to commence approximately 1 week later
- Premium packaging complete
- wheezo to be demonstrated to investors in a series of roadshows.






APP & PLATFORM

- wheezo™ app for iOS and Android core features complete
- Asthma journal features in progress
- Machine Learning platform in progress
- Focus groups to test app user experience (UX) scheduled for April
- wheezo to be demonstrated to investors in a series of roadshows.
- Amazon Web Services (AWS) committed to Respiri case study to coincide with product launch





REGULATORY PROCESS

Class IIa medical device




PRIORITY CLINICAL STUDIES

1. Comparison Study	2. Correlation Study	3. Longitudinal Health-Outcomes Study
To demonstrate that wheezo™ is as good as a doctor's stethoscope <i>Commencing April 2019</i>	To assess the correlation between wheeze rate and a relevant clinical measure of lung function e.g. FEV ₁ and symptom score	To assess the outcomes of patient given wheezo™ for use at home and the impact on medical resources


1. RespiRI, Eastern Health and Swinburne University study conducted at Box Hill Hospital supervised by Principal Investigator, **Professor Frank Thien**. Protocol submitted for Ethics Approval. Study outcomes published to coincide with wheezo™ launch.
2. Short term head to head comparison of wheeze rate with other lung function measure to be conducted as a follow-on to the comparison study. Two possible settings identified; acute care and primary care. Ethics Approval slightly more complex than Study 1 to be submitted shortly.
3. Longitudinal study key questions: Can wheezo™ predict increase in symptoms, predict exacerbations and have a positive impact on healthcare resources? **Important outcomes: Does regular use of wheezo™ improve quality of life, sleep, activity participation, school attendance and attack frequency?**

LAUNCH ECOSYSTEM



CAPTURING LEADS

Paid & Free Social Posts



Registration Page




Drive them to wheezo content hub

Customer Registers Interest



Customer doesn't register Interest



@wheezo.official
live with first posts
on Facebook &
Instagram
Friday 5 April 2019

CONTENT STRATEGY

Primary objective of wheezo

To provide reassurance for parents of children with asthma

Objective of comms

To drive awareness of wheezo and ultimately to drive sales

Our Target market comprises of:

Primary

- Parents of children with Asthma

Secondary

- HCP professionals
- Investors



Value proposition

The content we produce helps wheezo develop a leadership position in asthma and grow brand awareness.

By providing informative and inspiring content, we'll become a thought leader in asthma technology.

Content type

- Videos
- White papers
- Infographics
- News articles
- Tips & tricks

Content Pillars (Consumer)

- Educate
- Inspire
- Delight
- Support

Channels

- Website blog
- Facebook
- LinkedIn
- Instagram
- Newsletter
- Youtube
- Press releases
- SEO implications

Key metrics

- Views
- Shares
- Likes
- Open rate/clicks
- Leads generated
- Time spent on page
- Followers
- Sales

HEALTHCARE PROFESSIONALS CAMPAIGN



- 28 March – 2 April 2019 | Exhibit
- The Annual Scientific Meeting of The Australia and New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand
- Respiri to introduce and demonstrate wheezo™ to a captive audience of key opinion leaders, the multinational brands in medical devices and Big Pharma companies
- All key participants in Australasian respiratory medicine will be in attendance
- Prof Bruce Thompson inauguration as President of TSANZ


Pillars	Educate	Wheeze rate	Impact	Experience
Focus	Understand the science & technology	Educate HCP's about wheeze rate and what it means.	Understand wheezo's importance for my practice	GP experience with the device
Example Content	What is the technology behind wheezo	Clinical trial updates (Comparison study #1 - to demonstrate that wheezo is)	Testimonials of GPs/ KOLs	How to video & support guide Product familiarisation program

AMBASSADOR PROGRAM



Michael and Kyly Clarke open up about three-year-old daughter's hospitalisation after struggling to breathe

By Britt Middleton | 4 days ago



Michael Clarke content is in production with first posts on wheezo & personal channels coming soon.


INDIA A KEY RESPIRATORY MARKET

- It is critical to partner with local leaders to realise the significant potential for RespiRI and the wheezo™ brand in India
- Fast path to market in India via recognition of CE regulatory approval, no additional formal study/trial requirements, and ability to integrate software into Indian hospitals
- RespiRI has flexibility in its go-to-market strategy and recognises the viability of a B2B model in India that utilises medical practitioners and mostly private hospital networks
- The World Health Organisation has a requirement for the Air Quality Index (AQI) to be under 100¹ In much of India, the lowest the AQI will get to is 150-300, and peaks between 500-600. **22 of the top 30 most polluted cities in the world are in India**²
- Current population of ~1.4 billion (4 x USA), that is forecast to grow significantly over the next 10-15 years along with urbanisation
- Air pollution issues are likely to increase, causing additional pressure on the existing challenge to improve respiratory care



1.24 million air pollution deaths in India last year with respiratory diseases such as asthma and COPD one of the leading causes

India's air quality is now far worse than China's ever was



1. <https://www.who.int/airpollution/en/>
2. <https://edition.cnn.com/2019/03/04/>

RESPIRI RECEIVES BEST PRACTICE AWARD

Frost & Sullivan Best Practices Awards are independent, research backed accolades that recognise companies throughout a range of regional and global markets. Its industry analyst team benchmarks market participants and measures their performance through independent primary interviews and secondary industry research in order to evaluate and identify best practices.

Frost & Sullivan analysts independently evaluated the performance of Respiri and other companies in healthcare technology on two key factors – **Technology Attributes and Future Business Value.**

To support its evaluation of best practices across multiple business performance categories, Frost & Sullivan employs a customised Decision Support Scorecard to allow research and consulting teams to objectively analyse performance according to key benchmarking criteria and to assign ratings on that basis. Respiri rated well above its identified competitors to secure the 2019 Best Practices Award.

The full report will be made available to shareholders on respiri.co today.



RESPIRI



CONTACT:

MARIO GATTINO
CEO & DIRECTOR

+61 457 722 055
+61 3 9653 9160
mario@respiri.co

respiri.co
wheezo.com

RESPIRI LIMITED [ASX:RSH]
Level 27 101 Collins Street Melbourne
Victoria 3000 Australia

Registered office: 10/446 Collins Street Melbourne Victoria 3000 Australia

GERRY BULLON
INVESTOR RELATIONS

+61 418 106 675
gerry.bullon@insor.com.au

About Respi Limited

Respi's mission is to help improve quality of life for millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. The Company offers sensors, mobile apps and analytics to support respiratory health management. Its world first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respi's innovative platform provides personalised feedback and education based on the user's data and enables the sharing of that data with caregivers and health care providers. Respi Limited's operations are based in Melbourne, Australia.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi's current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.